V1RD20 Inhibitors
V1RD20 inhibitors pertain to a chemical class specifically designed to interact with the biological pathway associated with the V1RD20 protein. This protein, encoded by a corresponding gene, plays a crucial role in a specific biochemical cascade within organisms. The inhibitors are typically small molecules, crafted through a meticulous process of chemical synthesis and optimization. Their molecular structures are characterized by the presence of functional groups that enable them to bind with high affinity to the active or allosteric sites of the V1RD20 protein. The binding process involves a variety of non-covalent interactions such as hydrogen bonding, hydrophobic forces, van der Waals interactions, and possibly ionic bonds, depending on the particular chemical nature of the inhibitor and the amino acid residues that line the binding site of the protein.
The development of V1RD20 inhibitors is a sophisticated endeavor that involves a deep understanding of the protein's structure and function. Researchers utilize techniques such as X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy to elucidate the three-dimensional conformation of the V1RD20 protein. This structural information is critical as it guides the design of inhibitors to ensure complementarity to the target site. Additionally, computational methods such as molecular docking and dynamics simulations play a substantial role in predicting how these inhibitors might interact with the protein at an atomic level, allowing chemists to refine these molecules before they are synthesized in the lab. The complexity of the inhibitor design also takes into account the pharmacokinetic and pharmacodynamic properties, ensuring that these molecules are not only potent in their action but also exhibit suitable characteristics that allow them to reach and interact with the V1RD20 protein effectively within the biological context.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR inhibitor that prevents the activation of EGFR-dependent pathways, which may be upstream of V1RD20 activation. By inhibiting EGFR, Erlotinib could reduce the functional activity of V1RD20 if V1RD20 is part of the EGFR signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTOR signaling pathway. Since mTOR is involved in cell growth and survival, its inhibition by Rapamycin could indirectly lead to decreased activity of V1RD20 if V1RD20 is regulated by mTOR-dependent signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that impairs the PI3K/Akt signaling pathway, which may intersect with V1RD20's functional pathway. Inhibition of PI3K could lead to a decrease in V1RD20 activity if V1RD20 is modulated by Akt or downstream components. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a tyrosine kinase inhibitor with specificity for VEGFR, PDGFR, and Raf kinases. If V1RD20 is involved in signaling pathways mediated by these kinases, Sorafenib could reduce V1RD20 activity by inhibiting these pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that blocks the MAPK/ERK pathway. If V1RD20's activity is modulated by the MAPK/ERK pathway, Trametinib could lead to a reduction in its functional activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that impedes cell cycle progression. If V1RD20 is involved in cell cycle regulation pathways, Palbociclib could indirectly decrease V1RD20 activity by halting progression at the G1 phase. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
Venetoclax is a Bcl-2 inhibitor that promotes apoptosis. If V1RD20's function is related to cell survival and it interacts with the Bcl-2 family, Venetoclax could indirectly decrease V1RD20 activity by inducing apoptosis. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase inhibitor that affects B-cell receptor signaling. If V1RD20 is associated with B-cell receptor pathways, Ibrutinib could decrease V1RD20 activity by blocking this signaling route. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a Bcr-Abl tyrosine kinase inhibitor that also inhibits c-Kit and PDGFR. If V1RD20's activity is linked to the function of these kinases, Imatinib could lead to a decrease in V1RD20's functional activity. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide modulates the degradation of proteins by the proteasome. If V1RD20's stability or activity is regulated through proteasomal degradation, Thalidomide could potentially lead to reduced V1RD20 activity. | ||||||